HC Wainwright Brokers Raise Earnings Estimates for SRTS

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Equities researchers at HC Wainwright boosted their Q4 2025 earnings per share (EPS) estimates for Sensus Healthcare in a research report issued on Friday, May 16th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.20 per share for the quarter, up from their previous forecast of $0.19. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.20 EPS.

Several other research analysts also recently commented on SRTS. Maxim Group decreased their price objective on Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Monday. Lake Street Capital reduced their price target on Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, Wall Street Zen downgraded Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Thursday. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $11.67.

Sensus Healthcare Stock Performance

NASDAQ:SRTS traded down $0.03 during trading hours on Monday, reaching $4.68. The company's stock had a trading volume of 57,808 shares, compared to its average volume of 209,243. The firm has a 50-day simple moving average of $4.62 and a 200-day simple moving average of $6.08. Sensus Healthcare has a 1 year low of $4.01 and a 1 year high of $9.33. The firm has a market capitalization of $77.20 million, a price-to-earnings ratio of 11.70 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). The firm had revenue of $8.34 million during the quarter, compared to the consensus estimate of $7.23 million. Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Hedge Funds Weigh In On Sensus Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of SRTS. JPMorgan Chase & Co. purchased a new position in Sensus Healthcare during the 4th quarter valued at about $27,000. Barclays PLC bought a new stake in shares of Sensus Healthcare in the 4th quarter worth approximately $35,000. Larson Financial Group LLC purchased a new position in shares of Sensus Healthcare during the first quarter valued at approximately $26,000. BNP Paribas Financial Markets purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at approximately $47,000. Finally, IFP Advisors Inc purchased a new stake in Sensus Healthcare in the fourth quarter worth $95,000. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.